Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical stage neuropsychiatry company focused on transforming mental healthcare through proprietary drug discovery and delivery technologies, announced that Chief Business Officer George Tziras will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference scheduled for November 10-12, 2025, in Boston, Massachusetts. This participation underscores the increasing recognition of psychedelic-based therapies within mainstream healthcare investment circles and represents a significant opportunity for Cybin to showcase its clinical advancements to institutional investors and healthcare leaders.

The company's participation in this prestigious conference comes at a critical juncture in its development pipeline. Cybin is currently advancing CYB003, a proprietary deuterated psilocin analog, through Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over available therapies for serious conditions. The designation typically accelerates the development and review process for drugs intended to treat serious conditions when preliminary clinical evidence suggests they may offer significant advantages over existing treatments.

In addition to CYB003, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of neuropsychiatry innovation. Cybin's approach to mental healthcare involves developing new and innovative next-generation treatment options designed to address the large unmet need for people suffering from mental health conditions. The company's promising class-leading data suggests potential for changing the mental health treatment landscape through novel drugs that could provide effective and durable results for patients.

The Guggenheim Healthcare Innovation Conference provides an important platform for Cybin to discuss its progress and future prospects with the investment community. Institutional conferences of this caliber typically attract sophisticated healthcare investors, analysts, and industry professionals who play crucial roles in shaping market perceptions and investment decisions. Cybin's inclusion in this event reflects the growing acceptance and interest in psychedelic-derived therapies within traditional healthcare and investment frameworks. Additional information about Cybin is available through the company's newsroom at https://ibn.fm/CYBN. The conference participation represents a strategic opportunity for Cybin to communicate its value proposition and clinical milestones to key stakeholders in the healthcare investment ecosystem.